MiCo Make Strategic Investment in and Partnership with Trinity Biotech 

PUBLISHED: 11th April 2022

Photo to illustrate article https://www.lkshields.ie/images/uploads/news/Web_-_MiCo.png.

LK Shields Solicitors LLP was delighted to act as Irish counsel in support of Nelson Mullins Riley & Scarborough for their long-standing client MiCo Ltd on the Irish aspects of their agreement to make a strategic investment in and partnership with Trinity Biotech Plc. 

Trinity Biotech Plc is a NASDAQ-listed leading global diagnostic company with a broad range of clinical diagnostic products across infection diseases, haemoglobins and autoimmunity and a pan-global market presence. 

MiCo Ltd is a KOSDAQ-listed and Korea-based company engaged in the biomedical businesses in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors.

The investment comprises of ADSs along with an unsecured junior convertible loan note comprising a combined investment of $45 million.

 The conclusion of this investment is subject to customary Korean central bank approvals and is expected to close before the end of April 2022.

The team at LK Shields LLP was led by Richard Curran (Corporate Partner) along with Lester Sosa-Villatoro (Senior Corporate Associate) and Kristopher O’Shea (Corporate Associate) and supported by Simon Mahon (Finance Partner).

By using this website you allow us to place cookies on your computer. Our cookies do not personally identify you.